Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease

This study has been completed.
Information provided by:
Lundbeck LLC Identifier:
First received: July 27, 2005
Last updated: May 17, 2011
Last verified: May 2011
The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease. Subjects will be enrolled at approximately 20 investigational sites in the United States (U.S.) and 15 Ex-US sites. The maximum study duration will be 10 weeks. Subjects will have the option of continuing in an open-label extension study.

Condition Intervention Phase
Parkinson's Disease
Psychotic Disorders
Drug: Melperone HCl
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Melperone in the Treatment of Patients With Psychosis Associated With Parkinson's Disease

Resource links provided by NLM:

Further study details as provided by Lundbeck LLC:

Primary Outcome Measures:
  • Patient Evaluation of Symptoms of Psychosis. [ Time Frame: 6 weeks (from Baseline to end of Maintenance Period) ]
    The change in the Scale for Assessment of Positive Symptoms (SAPS) total score. The SAPS total score ranges from 0 to 170, with higher scores indicating more severe psychosis.

Secondary Outcome Measures:
  • Investigator/Caregiver Evaluations of Motor Function [ Time Frame: 6 weeks (from Baseline to end of Maintenance Period) ]
    The change in the motor section of the Unified Parkinson's Disease Rating Scale (UPDRS III - motor exam) score. Scores on the UPDRS III - motor exam range from 0 to 108, with higher scores indicating more severe motor symptoms.

Enrollment: 90
Study Start Date: July 2005
Study Completion Date: April 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Melperone HCl - 20 mg Drug: Melperone HCl
20 mg/day. Strength of melperone syrup is 5 mg/mL
Experimental: Melperone HCl - 40 mg Drug: Melperone HCl
40 mg/day. Strength of melperone syrup is 5 mg/mL
Experimental: Melperone HCl - 60 mg Drug: Melperone HCl
60 mg/day. Strength of melperone syrup is 5 mg/mL
Placebo Comparator: Placebo Drug: Placebo
Syrup formulation

Detailed Description:
Parkinson's Disease is a progressive neurodegenerative disorder characterized by bradykinesia, rigidity, tremor and abnormal posture and gait. Many patients can have mild to moderate symptoms, while others with advanced disease have symptoms which interfere with activities of daily living to a severe degree. Although effective in addressing motor dysfunction, long-term use of anti-Parkinsonian agents has been implicated as a component in the development of psychiatric side effects including psychosis. Treatment of psychosis with typical antipsychotics is not recommended in this patient population, since even low potency typical antipsychotics can cause marked exacerbations of parkinsonism in Parkinson's disease patients. The use of atypical antipsychotics (e.g., clozapine, risperidone and quetiapine) has shown some efficacy in the treatment of psychosis in PD patients. Melperone is classified atypical antipsychotic. European experience with melperone spans more than 30 years, and it encompasses an established antipsychotic efficacy profile in the treatment of confusion, anxiety, unrest (particularly in the elderly) and schizophrenia as well as a favorable safety and tolerability profile. Eligible subjects with Parkinson's disease psychosis will participate in a 1-2 week Screening/Washout Period, a 5 week Titration Phase (one of three doses of melperone or placebo), a 1 week Maintenance Phase and a Taper/Follow-up Period up to 2 weeks. Following the Day 43 assessment, subjects may be given the option of receiving melperone in an open-label extension study.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The subject or subject's legally authorized representative (LAR) must sign and date the IRB/IEC approved Informed Consent Form and HIPAA Authorization (applicable to US sites only) prior to study participation.
  • Male or female subjects. If female:

    • Subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or if of childbearing potential, must comply with a method of birth control acceptable to the investigator during the study, for at least one month prior to randomization and for one month following completion of the study.
    • Subject is not breastfeeding
    • Subjects of childbearing potential must have a negative serum pregnancy test at the screening visit and on Day 1.
  • Subjects with a clinical diagnosis of idiopathic Parkinson's Disease, defined as the presence of at least three of the following cardinal features, in the absence of alternative explanations or atypical features:

    • Rest tremor
    • Rigidity
    • Bradykinesia and/or akinesia
    • Postural and gait abnormalities
  • Subjects with psychosis:

    • Presence of visual and/or auditory hallucinations, with or without delusions, occurring during the four weeks prior to the screening visit.
    • Symptoms severe enough to clinically warrant treatment with an antipsychotic agent.
    • A Hallucinations or Delusions total item score (frequency x severity) of > 4 on the Neuropsychiatric Inventory (NPI).

      • Subjects currently being treated with an antipsychotic agent who have not had visual and/or auditory hallucinations, with or without delusions, during the four weeks prior to screening, and/or have a Hallucinations or Delusions total item score <4 on the NPI at the screening visit may be washed out (for 7 days or 5 half-lives, whichever is longer) and return for a repeat screening visit. The NPI Hallucinations or Delusions total item score must be ≥4 at the repeat visit to be considered for study entry.
  • Subject is on a stable dose of anti-Parkinsonian medication(s) for at least 7 days or 5 half-lives, whichever is longer, prior to the screening visit and is expected to remain on a stable dose for the duration of the study.
  • Subject is willing and able to comply with all study procedures.

Exclusion Criteria:

  • Subject has any systemic factor contributing to the psychosis such as urinary infection, liver disease, renal failure, anemia, infection or cancer.
  • Subject has a history of significant psychotic disorders prior to the diagnosis of Parkinson's Disease, including but not limited to schizophrenia or bipolar disorder.
  • Subject has Dementia with Lewy-bodies (DLB).
  • Subject has dementia or a major depressive disorder precluding accurate assessment on rating scales.
  • Subject has an acute depressive episode at the time of the screening visit.
  • A score on the Mini-Mental State Examination (MMSE) of < 21.
  • Subject has had a dose adjustment of their antidepressant medication within 30 days prior to the screening visit, or dose adjustments are planned during the duration of the trial.
  • Subject has had dose adjustments of an anxiolytic, cognitive enhancer, or other psychotropic medication (excluding antipsychotics) within 30 days prior to screening or dose adjustments are planned during the duration of the trial.
  • Subject has received depot antipsychotic agents within the past 3 months.
  • Subject has previously failed treatment with clozaril for psychosis in Parkinson's disease. Subjects who discontinued clozaril due to intolerability may be enrolled.
  • Subject has used any investigational product within 30 days or 5 half-lives, whichever is longer, prior to screening.
  • Subject cannot tolerate a wash-out of antipsychotic medication prior to randomization.
  • Subject has a history of a serious respiratory, gastrointestinal, renal, hematologic or other medical disorder.
  • Subject has a history of a serious cardiovascular condition (including, but not limited to, Class IV angina or Class IV heart failure) and/or a history of risk factors for Torsade de pointes (Tdp) (including but not limited to current treatment for hypokalemia or family history of long QT syndrome).
  • Subject had myocardial infarction within 6 months prior to screening.
  • Subject has a screening ECG with corrected QT interval by Bazett's correction formula (QTcB) of greater than 450 msec, if female, or 430 msec, if male.
  • Subject requires treatment with an α-agonist agent.
  • Subject has uncontrolled seizures, uncontrolled angina, or uncontrolled symptomatic orthostatic hypotension (or orthostatic hypotension leading to a history of falls 3 months prior to screening), or other medical disorders which would make the subject a poor candidate for a clinical trial.
  • Subject has a history of severe adverse reactions to antipsychotic medications and/or quinine.
  • Subject has clinically significant abnormal laboratory values, ECG, or findings on physical exam.
  • Subject has a recent history or current evidence of substance dependence or abuse.
  • Subject is unable to ingest liquid medication.
  • Subject is currently being treated with Deep Brain Stimulation (DBS).

Randomization Criteria

  • Subject has a Hallucinations or Delusions total item score (frequency x severity) of > 4 on the NPI.
  • Female subjects of childbearing potential must have a negative serum pregnancy test.
  • Subject has remained on a stable dose of anti-Parkinsonian medications.
  • Subject has not had a dose adjustment in their antidepressant medication since the screening visit.
  • Subjects have been washed out of previous antipsychotic agents for 5 half-lives or 7 days, whichever is longer, after the last dose of medication.
  • Subject has not had dose adjustments in an anxiolytic, cognitive enhancer or other psychotropic medication (excluding antipsychotics) since the Screening Visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00125138

United States, Arizona
Northwest Neurospecialists, PLLC
Tucson, Arizona, United States, 85741
United States, Florida
Bradenton Research Center, Inc
Bradenton, Florida, United States, 34205
University of South Florida
Tampa, Florida, United States, 33606
United States, Kansas
The University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
United States, Michigan
Quest Research Institute
Bingham Farms, Michigan, United States, 48025
United States, Minnesota
Struthers Parkinson's Center, Park Nicollet Health Services
Golden Valley, Minnesota, United States, 55427
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, North Carolina
Neurology Consultants of the Carolinas
Charlotte, North Carolina, United States, 28204
United States, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45267
United States, Texas
Neurology Associates
San Antonio, Texas, United States, 78217
Department of Neurology, Rajendra Prasad Ward, King George Hospital, Visakhapatnam
Visakhapatnam, Andhra Pradesh, India, 530 002
Department of Neurology, Manipal Hospital
Bangalore, Karnataka, India, 560017
M. S. Ramasah Memorial Hospital
Bangalore, Karnataka, India, 560054
KLE Hospital, Belgaum
Belgaum, Karnataka, India, 590 010
Kasturra Medical College, Hospital, Attavar
Mangalore, Karnataka, India, 575 001
Trivandrum, Kerla, India, 695 011
Jaslok Hospital and Research Center
Mumbai, Maharastra, India, 400 026
Apollo Hospitals Educational and Research Foundation
Chennai, Tamilnadu, India, 600 006
Fondazione Universita di Chieti C.E.S.I. Centro Studi sull'Invecchiamento
Chieti Scalo, Ambruzzo, Italy, 66013
U.O. Neurologia IRCCS San Raffaele Pisana
Rome, Lazio, Italy, 00163
IRCCS Centro Neurolesi "Bonino Pulejo"
Messina, Sicily, Italy, 98124
Sponsors and Collaborators
Lundbeck LLC
Study Director: Email contact via H. Lundbeck A/S
  More Information

Responsible Party: Lundbeck Inc. Identifier: NCT00125138     History of Changes
Other Study ID Numbers: 13104A
OV1003 ( Other Identifier: Former study ID )
Study First Received: July 27, 2005
Results First Received: April 11, 2011
Last Updated: May 17, 2011

Additional relevant MeSH terms:
Parkinson Disease
Mental Disorders
Psychotic Disorders
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Schizophrenia Spectrum and Other Psychotic Disorders
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs processed this record on May 23, 2017